Discontinuing Metformin in Patients with A1C Levels Below 6.5%

Introduction to Discontinuation

The American College of Physicians recommends deintensifying pharmacologic therapy when A1C falls below 6.5%, as no trials demonstrate improved clinical outcomes with targets below this threshold 1
Discontinuing metformin at an A1C of 5.9% is appropriate, as it exposes the patient to medication burden, costs, and potential adverse effects without demonstrated benefit 1, 2

The ACCORD trial, which targeted A1C <6.5% and achieved 6.4%, was terminated early due to increased overall mortality, cardiovascular death, and severe hypoglycemia 1
The ADVANCE study found no statistically significant clinical benefit at an achieved A1C of 6.4% compared to 7.0%, while demonstrating more adverse effects 1
The American College of Physicians notes that even metformin has uncertain benefit-to-harm balance at A1C levels below 7% 1

If the patient achieved an A1C of 5.9% primarily through lifestyle modifications rather than metformin, discontinuation is even more appropriate 2
Patients with life expectancy >10 years and who desire intensive control may consider continuing metformin; if <10 years or age ≥80, discontinuation is particularly appropriate 1
Patients with dementia, end-stage kidney disease, severe heart failure, or nursing home residents should prioritize symptom management over A1C targets 1

Reduce metformin dose by 50% initially rather than abrupt cessation 2
After 2-4 weeks, discontinue completely if glycemic control remains stable 2
If patient is on multiple antidiabetic agents, eliminate metformin first as it has the lowest risk profile 2

Recheck A1C in 3 months after discontinuation 2
Educate patient on hyperglycemia symptoms and consider home glucose monitoring if A1C begins trending upward 2
If A1C rises to ≥6.5% after discontinuation, strongly consider reinitiating metformin 1
Do not discontinue metformin if the patient has established cardiovascular disease, heart failure, or chronic kidney disease where metformin may provide benefits beyond glycemic control 3, 4